Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning
NCT03806751 · University of Alabama at Birmingham · EARLY_PHASE1 · withdrawn · last registry update 2024-03-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The investigator decided not to pursue the study.” | – | Registry record, University of Alabama at Birmingham |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-14Also stopped (terminated): Stadtspital Zürich, Furosemide + Metolazone (NCT05986773)
- 2025-01-31Also stopped (terminated): Aziende Chimiche Riunite Angelini Francesco S.p.A, 380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily + 380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily (NCT05204667)
- 2025-01-20Phase 3 first posted: Mansoura University, Dapagliflozin 10mg + Acetazolamide 500mg (NCT06783166)
- 2024-10-28Results posted on the registry: Ziekenhuis Oost-Limburg, Acetazolamide + Placebo (NCT03505788)
- 2024-09-25Also stopped (withdrawn): Henry Ford Health System, Acamprosate + Placebo (NCT06312800)
- 2024-08-19Phase 3 first posted: Campbell Clinic, Opiate Sparing + Opiate Based (NCT06561035)
- 2024-08-02Phase 3 first posted: Helwan University, Acetazolamide + Dapagliflozin 10mg (NCT06535529)
- 2024-05-02Results posted on the registry: University of California, San Diego, Acetazolamide + Eszopiclone (NCT04639193)
- 2024-01-31Results posted on the registry: Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2024-01-31Also stopped (terminated): Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2024-01-03Results posted on the registry: CrystalGenomics, Inc., CG100649 + Ketoconazole (NCT01154764)
- 2023-12-12Phase 3 first posted: Johannes Grand, Acetazolamide + Metolazone 2.5 MG (NCT06166654)
- 2023-11-24Phase 3 first posted: Incannex Healthcare Ltd, IHL-42X Low Dose + IHL-42X High Dose (NCT06146101)
- 2023-07-27Results posted on the registry: University of Wisconsin, Madison, Acetazolamide (NCT03377049)
- 2023-07-11Phase 3 first posted: Tehran University of Medical Sciences, a drug against CA1 (NCT05940220)
- 2023-04-27Also stopped (terminated): The University of Texas Health Science Center, Houston, Acetazolamide + Placebo (NCT02466074)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision